DARK Classics in Chemical Neuroscience: Psilocybin
Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in...
Gespeichert in:
Veröffentlicht in: | ACS chemical neuroscience 2018-10, Vol.9 (10), p.2438-2447 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2447 |
---|---|
container_issue | 10 |
container_start_page | 2438 |
container_title | ACS chemical neuroscience |
container_volume | 9 |
creator | Geiger, Haden A Wurst, Madeline G Daniels, R. Nathan |
description | Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present. |
doi_str_mv | 10.1021/acschemneuro.8b00186 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2062836850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2062836850</sourcerecordid><originalsourceid>FETCH-LOGICAL-a348t-4a653dc7704ff301314e8de4744f45338a4b1b9a2b545e1efd2993644c99fa6a3</originalsourceid><addsrcrecordid>eNp9kEtPwzAQhC0EoqXwDxDKkUuKHW8cm1uV8hIVIARny3E2wlUeJW4O_fe4akE9cdo9fDM7O4RcMjplNGE3xnr7hU2LQ99NZUEpk-KIjJkCGWdM8eODfUTOvF9SKhSV4pSMEqVSoVg2Jsl89v4c5bXx3lkfuTbKg6mzpo5ets7eOmwt3kZv3tWd3RSuPScnlak9XuznhHze333kj_Hi9eEpny1iw0GuYzAi5aXNMgpVxSnjDFCWCBlABSnn0kDBCmWSIoUUGVZlSMUFgFWqMsLwCbne-a767ntAv9aN8xbr2rTYDV4nVCSSC5nSgMIOtSGx77HSq941pt9oRvW2LX3Ylt63FWRX-wtD0WD5J_qtJwB0BwS5XnZD34aH__f8AeQueE4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2062836850</pqid></control><display><type>article</type><title>DARK Classics in Chemical Neuroscience: Psilocybin</title><source>ACS Publications</source><creator>Geiger, Haden A ; Wurst, Madeline G ; Daniels, R. Nathan</creator><creatorcontrib>Geiger, Haden A ; Wurst, Madeline G ; Daniels, R. Nathan</creatorcontrib><description>Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present.</description><identifier>ISSN: 1948-7193</identifier><identifier>EISSN: 1948-7193</identifier><identifier>DOI: 10.1021/acschemneuro.8b00186</identifier><identifier>PMID: 29956917</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>ACS chemical neuroscience, 2018-10, Vol.9 (10), p.2438-2447</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a348t-4a653dc7704ff301314e8de4744f45338a4b1b9a2b545e1efd2993644c99fa6a3</citedby><cites>FETCH-LOGICAL-a348t-4a653dc7704ff301314e8de4744f45338a4b1b9a2b545e1efd2993644c99fa6a3</cites><orcidid>0000-0001-8482-8208</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acschemneuro.8b00186$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acschemneuro.8b00186$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29956917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geiger, Haden A</creatorcontrib><creatorcontrib>Wurst, Madeline G</creatorcontrib><creatorcontrib>Daniels, R. Nathan</creatorcontrib><title>DARK Classics in Chemical Neuroscience: Psilocybin</title><title>ACS chemical neuroscience</title><addtitle>ACS Chem. Neurosci</addtitle><description>Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present.</description><issn>1948-7193</issn><issn>1948-7193</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kEtPwzAQhC0EoqXwDxDKkUuKHW8cm1uV8hIVIARny3E2wlUeJW4O_fe4akE9cdo9fDM7O4RcMjplNGE3xnr7hU2LQ99NZUEpk-KIjJkCGWdM8eODfUTOvF9SKhSV4pSMEqVSoVg2Jsl89v4c5bXx3lkfuTbKg6mzpo5ets7eOmwt3kZv3tWd3RSuPScnlak9XuznhHze333kj_Hi9eEpny1iw0GuYzAi5aXNMgpVxSnjDFCWCBlABSnn0kDBCmWSIoUUGVZlSMUFgFWqMsLwCbne-a767ntAv9aN8xbr2rTYDV4nVCSSC5nSgMIOtSGx77HSq941pt9oRvW2LX3Ylt63FWRX-wtD0WD5J_qtJwB0BwS5XnZD34aH__f8AeQueE4</recordid><startdate>20181017</startdate><enddate>20181017</enddate><creator>Geiger, Haden A</creator><creator>Wurst, Madeline G</creator><creator>Daniels, R. Nathan</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8482-8208</orcidid></search><sort><creationdate>20181017</creationdate><title>DARK Classics in Chemical Neuroscience: Psilocybin</title><author>Geiger, Haden A ; Wurst, Madeline G ; Daniels, R. Nathan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a348t-4a653dc7704ff301314e8de4744f45338a4b1b9a2b545e1efd2993644c99fa6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geiger, Haden A</creatorcontrib><creatorcontrib>Wurst, Madeline G</creatorcontrib><creatorcontrib>Daniels, R. Nathan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>ACS chemical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geiger, Haden A</au><au>Wurst, Madeline G</au><au>Daniels, R. Nathan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DARK Classics in Chemical Neuroscience: Psilocybin</atitle><jtitle>ACS chemical neuroscience</jtitle><addtitle>ACS Chem. Neurosci</addtitle><date>2018-10-17</date><risdate>2018</risdate><volume>9</volume><issue>10</issue><spage>2438</spage><epage>2447</epage><pages>2438-2447</pages><issn>1948-7193</issn><eissn>1948-7193</eissn><abstract>Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>29956917</pmid><doi>10.1021/acschemneuro.8b00186</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8482-8208</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1948-7193 |
ispartof | ACS chemical neuroscience, 2018-10, Vol.9 (10), p.2438-2447 |
issn | 1948-7193 1948-7193 |
language | eng |
recordid | cdi_proquest_miscellaneous_2062836850 |
source | ACS Publications |
title | DARK Classics in Chemical Neuroscience: Psilocybin |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A53%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DARK%20Classics%20in%20Chemical%20Neuroscience:%20Psilocybin&rft.jtitle=ACS%20chemical%20neuroscience&rft.au=Geiger,%20Haden%20A&rft.date=2018-10-17&rft.volume=9&rft.issue=10&rft.spage=2438&rft.epage=2447&rft.pages=2438-2447&rft.issn=1948-7193&rft.eissn=1948-7193&rft_id=info:doi/10.1021/acschemneuro.8b00186&rft_dat=%3Cproquest_cross%3E2062836850%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2062836850&rft_id=info:pmid/29956917&rfr_iscdi=true |